Palliative care in day-hospital for advanced cancer patients: a study protocol for a multicentre randomized controlled trial.


Journal

BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685

Informations de publication

Date de publication:
17 Apr 2021
Historique:
received: 09 11 2020
accepted: 11 04 2021
entrez: 18 4 2021
pubmed: 19 4 2021
medline: 16 10 2021
Statut: epublish

Résumé

Team-based and timely integrated palliative care is a gold standard of care in oncology, but issues concerning its optimal organization remain. Palliative Care in Day-Hospital (PCDH) could be one of the most efficient service model of palliative care to deliver interdisciplinary and multidimensional care addressing the complex supportive care needs of patients with advanced cancer. We hypothesize that, compared to conventional outpatient palliative care, PCDH allows the clinical benefits of palliative care to be enhanced. This study is a multicentre parallel group trial with stratified randomization. Patient management in PCDH will be compared to conventional outpatient palliative care. The inclusion criteria are advanced cancer patients referred to a palliative care team with an estimated life expectancy of more than 2 months and less than 1 year. The primary endpoint is health-related quality of life with deterioration-free survival based on the EORTC QLQ-C30 questionnaire. The secondary objectives are the following: increase in patient satisfaction with care using the EORTC PATSAT-C33 and OUT-PATSAT7 questionnaires, better understanding of the prognosis using the PTPQ questionnaire and advance care planning; decrease in the need for supportive care among relatives using the SCNS-P&C-F questionnaire, and reduction in end-of-life care aggressiveness. Patients will complete one to five questionnaires on a tablet before each monthly visit over 6 months and will be followed for 1 year. A qualitative study will take place, aiming to understand the specificity of palliative care management in PCDH. Cost-effectiveness, cost-utility and, an additional economic evaluation based on capability approach will be conducted from a societal point of view. The first strength of this study is that it combines the main relevant outcomes assessing integrated palliative care; patient quality of life and satisfaction; discussion of the prognosis and advance care planning, family well-being and end-of-life care aggressiveness. The second strength of the study is that it is a mixed-method study associating a qualitative analysis of the specificity of PCDH organization, with a medical-economic study to analyse the cost of care. Name of the registry: IDRCB 2019-A03116-51 Trial registration number: NCT04604873 Date of registration: October 27, 2020 URL of trial registry record.

Sections du résumé

BACKGROUND BACKGROUND
Team-based and timely integrated palliative care is a gold standard of care in oncology, but issues concerning its optimal organization remain. Palliative Care in Day-Hospital (PCDH) could be one of the most efficient service model of palliative care to deliver interdisciplinary and multidimensional care addressing the complex supportive care needs of patients with advanced cancer. We hypothesize that, compared to conventional outpatient palliative care, PCDH allows the clinical benefits of palliative care to be enhanced.
METHODS/DESIGN METHODS
This study is a multicentre parallel group trial with stratified randomization. Patient management in PCDH will be compared to conventional outpatient palliative care. The inclusion criteria are advanced cancer patients referred to a palliative care team with an estimated life expectancy of more than 2 months and less than 1 year. The primary endpoint is health-related quality of life with deterioration-free survival based on the EORTC QLQ-C30 questionnaire. The secondary objectives are the following: increase in patient satisfaction with care using the EORTC PATSAT-C33 and OUT-PATSAT7 questionnaires, better understanding of the prognosis using the PTPQ questionnaire and advance care planning; decrease in the need for supportive care among relatives using the SCNS-P&C-F questionnaire, and reduction in end-of-life care aggressiveness. Patients will complete one to five questionnaires on a tablet before each monthly visit over 6 months and will be followed for 1 year. A qualitative study will take place, aiming to understand the specificity of palliative care management in PCDH. Cost-effectiveness, cost-utility and, an additional economic evaluation based on capability approach will be conducted from a societal point of view.
DISCUSSION CONCLUSIONS
The first strength of this study is that it combines the main relevant outcomes assessing integrated palliative care; patient quality of life and satisfaction; discussion of the prognosis and advance care planning, family well-being and end-of-life care aggressiveness. The second strength of the study is that it is a mixed-method study associating a qualitative analysis of the specificity of PCDH organization, with a medical-economic study to analyse the cost of care.
TRIAL REGISTRATION BACKGROUND
Name of the registry: IDRCB 2019-A03116-51 Trial registration number: NCT04604873 Date of registration: October 27, 2020 URL of trial registry record.

Identifiants

pubmed: 33865379
doi: 10.1186/s12904-021-00754-x
pii: 10.1186/s12904-021-00754-x
pmc: PMC8053288
doi:

Banques de données

ClinicalTrials.gov
['NCT04604873']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61

Subventions

Organisme : Institut National Du Cancer
ID : N°2019-006

Références

Health Qual Life Outcomes. 2012 Dec 17;10:151
pubmed: 23244763
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Palliat Med. 2014 Feb;28(2):151-7
pubmed: 23698452
J Palliat Med. 2016 Aug;19(8):863-9
pubmed: 27124211
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Curr Treat Options Oncol. 2019 Feb 11;20(2):17
pubmed: 30741353
J Oncol Pract. 2017 Sep;13(9):e760-e769
pubmed: 28829693
Int J Palliat Nurs. 2001 Sep;7(9):427-34
pubmed: 11832846
Oncologist. 2017 Dec;22(12):1528-1534
pubmed: 28894017
Breast Cancer Res Treat. 2018 Feb;167(3):703-708
pubmed: 29086230
J Clin Oncol. 2008 Aug 10;26(23):3860-6
pubmed: 18688053
J Oncol Pract. 2017 Sep;13(9):e729-e737
pubmed: 28562197
J Support Oncol. 2010 Jan-Feb;8(1):21-7
pubmed: 20235420
J Clin Oncol. 2018 Apr 10;36(11):1096-1102
pubmed: 29474102
J Clin Oncol. 2003 Mar 15;21(6):1133-8
pubmed: 12637481
CA Cancer J Clin. 2010 Sep-Oct;60(5):317-39
pubmed: 20709946
Psychooncology. 2017 Mar;26(3):400-404
pubmed: 27546090
J Clin Oncol. 2015 May 1;33(13):1446-52
pubmed: 25800762
CA Cancer J Clin. 2018 Sep;68(5):356-376
pubmed: 30277572
J Palliat Med. 2008 Dec;11(10):1304-8
pubmed: 19115888
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Health Econ. 2008 Jun;17(6):667-70
pubmed: 18457341
Int J Palliat Nurs. 2011 Dec;17(12):523
pubmed: 22240737
Eur J Cancer Care (Engl). 2019 Jan;28(1):e12896
pubmed: 30168874
Eur J Cancer. 2010 Oct;46(15):2753-62
pubmed: 20724140
Lancet Oncol. 2018 Nov;19(11):e588-e653
pubmed: 30344075
Lancet Oncol. 2018 Mar;19(3):394-404
pubmed: 29402701
J Clin Oncol. 2011 Apr 20;29(12):1587-91
pubmed: 21402603
Ann Oncol. 2017 Sep 1;28(9):2057-2066
pubmed: 28911084
J Pain Symptom Manage. 2010 Jul;40(1):126-35
pubmed: 20619215
Soc Sci Med. 2017 Sep;189:114-128
pubmed: 28797940
Palliat Med. 2010 Sep;24(6):630-40
pubmed: 20501512
J Clin Oncol. 2017 Mar 10;35(8):834-841
pubmed: 28029308
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
J Oncol Pract. 2017 Sep;13(9):e792-e799
pubmed: 28813191
J Clin Oncol. 2012 Feb 1;30(4):394-400
pubmed: 22203758
Curr Oncol. 2018 Feb;25(1):e54-e58
pubmed: 29507496
Eur J Cancer. 2020 Jan;124:186-193
pubmed: 31812934
BMJ. 2007 Mar 3;334(7591):455-9
pubmed: 17332585
Int J Qual Health Care. 2005 Dec;17(6):505-9
pubmed: 15985505
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 29094784
BMJ Open. 2018 Jan 31;8(1):e018284
pubmed: 29386222
J Pain Symptom Manage. 2016 Sep;52(3):378-85
pubmed: 27265814
Eur J Cancer. 2016 Dec;69:110-118
pubmed: 27821313
J Natl Cancer Inst. 2015 Jan 20;107(3):
pubmed: 25609233
BMC Palliat Care. 2017 Jan 25;16(1):10
pubmed: 28122560
BMC Palliat Care. 2019 Apr 5;18(1):35
pubmed: 30953487
Psychooncology. 2011 Apr;20(4):387-93
pubmed: 20878835
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129
pubmed: 28603881
Palliat Med. 2017 Oct;31(9):814-824
pubmed: 28494643
J Pain Symptom Manage. 2009 Jul;38(1):75-80
pubmed: 19615630
J Clin Oncol. 2012 Mar 10;30(8):880-7
pubmed: 22312101
Qual Life Res. 2015 Jan;24(1):5-18
pubmed: 24277234
Am Soc Clin Oncol Educ Book. 2018 May 23;38:111-121
pubmed: 30231351
Cancer. 2015 Oct 15;121(20):3737-45
pubmed: 26150131
Oncologist. 2016 Jul;21(7):895-901
pubmed: 27185614
Ann Fam Med. 2015 Nov;13(6):554-61
pubmed: 26553895

Auteurs

Laura Thery (L)

Department of Supportive and Palliative Care, Institut Curie, Paris, France. laura.thery@curie.fr.

Amélie Anota (A)

Biostatistics Unit, DRCI, Centre Léon Bérard, Lyon, France.
French National Platform Quality of Life and Cancer, Lyon, France.
INSERM, EFS-BFC, UMR 1098- Université de Bourgogne-Franche-Comté, Besançon, France.

Lorraine Waechter (L)

Department of Supportive and Palliative Care, Hôpital Cochin, Paris, France.

Celine Laouisset (C)

Department of Supportive and Palliative Care, Institut Curie, Paris, France.

Timothee Marchal (T)

Department of Supportive and Palliative Care, Institut Curie, Paris, France.

Alexis Burnod (A)

Department of Supportive and Palliative Care, Institut Curie, Paris, France.

Elisabeth Angellier (E)

Department of Supportive and Palliative Care, Institut Curie, Saint Cloud, Paris, France.

Oum El Kheir Djoumakh (OEK)

Methodological and Quality of Life Unit in Oncology (INSERM 1098), University Hospital, Besançon, France.

Clemence Thebaut (C)

Université de Limoges, UMR 1094 (NET), Limoges, France.
Université Paris-Dauphine, PSL Research, University, LEDa [Legos], Paris, France.

Anne Brédart (A)

Department of Psycho-Oncology, Institut Curie, Paris, France.
Laboratoire Psychopathologie et Processus de Santé, Université de Paris, F-92100, Boulogne Billancourt, Paris, France.

Sylvie Dolbeault (S)

Department of Psycho-Oncology, Institut Curie, Paris, France.

Jean-Christophe Mino (JC)

Department of Medical Ethics, Sorbonne University Medical School, Paris, France.

Carole Bouleuc (C)

Department of Supportive and Palliative Care, Institut Curie, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH